Effects of chelation with EDTA and vitamin B therapy on nitric oxide- related endothelial vasodilator function

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 11, 1999, Pages 853-856

  Green, Daniel J ^a,b   Driscoll, J Gerard ^b   Maiorana, Andrew ^a,b   Scrimgeour, Neil B ^c   Weerasooriya, Rukshen ^b   Taylor, Roger R ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c General Practice   (Australia)

Author keywords

Chelation; Endothelial function; Homocysteine; Vitamin B

Indexed keywords

ACETYLCHOLINE; EDETIC ACID; HOMOCYSTEINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; VITAMIN B GROUP;

ADULT; ARTICLE; CHELATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; HEART PROTECTION; HUMAN; MALE; PLETHYSMOGRAPHY; VASODILATATION;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; CHELATING AGENTS; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; EDETIC ACID; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITROPRUSSIDE; REGIONAL BLOOD FLOW; VASODILATION; VITAMIN B COMPLEX;

EID: 0032716663     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03156.x     Document Type: Article

References (26)

1. 1. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J. Cardiovasc. Nurs. 1996; 10: 78-86.
2. 2. van Rij AM, Solomon C, Packer SGK, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994; 90: 1194-9.
3. 3. Olszewer E, Sabbag FC, Carter JA. A pilot double-blind study of sodium magnesium EDTA in peripheral vascular disease. J. Natl Med. Assoc. 1990; 82: 173-7.
4. 4. Guldager B, Jelnes R, Jorgensen SJ et al. EDTA treatment of intermittent claudication: A double-blind, placebo-controlled study. J. Intern. Med. 1992; 231: 261-7.
5. 5. Sloth-Nielsen J, Guldager B, Mouitzen C et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am. J. Surg. 1991; 162: 122-5.
6. 6. Ernst E. Chelation therapy for peripheral arterial occlusive disease. A systematic review. Circulation 1997; 96: 1031-3.
7. 7. Schachter MB. Chelation therapy. Circulation 1995; 91: 2291-2.
8. 8. Chappell LT, Miranda R, Rubin M, Carter JP, Trowbridge J. Chelation therapy. Circulation 1995; 92: 1350-1.
9. 9. Jonas WB. Effectiveness of EDTA chelation therapy. Circulation 1995; 92: 1352.
10. 10. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 1994; 24: 1468-74.
11. 11. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
12. 12. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 1997; 100: 678-84.
13. 13. Benjamin N, Calver A, Collier J, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25: 918-23.
14. 14. Bouskey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274; 1049-57.
15. 15. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
16. 16. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998; 98: 196-9.
17. 17. Van den Berg M, Boers GHJ. Homocystinuria: What about mild hyperhomocysteinemia? Postgrad. Med. J. 1996; 72: 513-18.
18. 18. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler. Thromb. 1994; 14: 465-70.
19. 19. Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J. Clin. Invest. 1996; 98: 24-9.
20. 20. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
21. 21. Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest. 1993; 91: 308-18.
22. 22. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
23. 23. Robinson K, Mayer EL, Miller DP et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
24. 24. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 1997; 100: 2153-7.
25. 25. Grier MT, Meyers DG. So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann. Pharmacother. 1993; 27: 1504-9.
26. 26. Hayashi T, Ishikawa T, Kuzuya M et al. Chelation of copper reduces inhibition by oxidized lipoproteins of endothelium-dependent relaxation in porcine coronary arteries. Heart Vessels 1994; 9: 283-91.